

BIOMARKER

summit

Includes the three co-located conferences:

9th Oncology Biomarkers

5th Neurological Biomarkers

5th Inflammatory & Immunological Biomarkers

MARCH 21-23, 2016 • SAN DIEGO, CA

Platinum Sponsor

MYRIAD  RBM

Gold Sponsors

SomaLogic

Quanterix
high definition diagnostics

 Viracor-IBT
LABORATORIES


CAPRION

 Sbio®
BRINGING GLYCOMICS TO LIFE®


SOUTHERN
RESEARCH

Solving the world's
hardest problems.

Silver Sponsors

OLINK
BIOSCIENCE

illumina®

ABOUT

The **Biomarker Summit 2016**, to be held on **March 21-23, 2016** in **San Diego, CA** at the Westin San Diego Hotel, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization. The Summit is comprised of three co-located conferences:

9th Oncology Biomarkers - This conference brings together experts in industry, academia and government to discuss the latest developments in the oncology biomarker research arena. Hot topics include circulating tumor cells, cell free DNA, digital pathology and imaging biomarkers. Applications of technologies such as mass spectrometry and next generation sequencing as well as data analysis and interpretation will also be discussed.

5th Neurological Biomarkers - This conference focuses on the development of CNS biomarkers for drugs and diagnostics from CSF and Blood, as well as imaging approaches. Scientific data, updates and case studies in neurological and neurodegenerative disorders will be presented on disease areas such as Alzheimer's, Parkinson's and Huntington's. Biomarker challenges for neuropsychiatric disorders such as autism, schizophrenia, depression and mood disorder will also be explored.

5th Inflammatory & Immunological Biomarkers - This conference will cover both inflammatory and immunological biomarkers in a wide variety of disease areas. The unmet medical needs in autoimmune diseases, respiratory diseases, kidney disease, lupus, IBD and other inflammatory diseases will be discussed. Presentations and case studies from both industry and academia will cover predictive biomarkers, surrogate endpoints and improving clinical trials as it relates to both drug and diagnostic development.

POSTER & ORAL PRESENTATION OPPORTUNITIES

If you are interested in participating in the Summit's poster session to showcase your work and research, please submit an abstract [here](#) and select which conference you would like to present in by **February 21, 2016**. In addition, the top two to three abstracts submitted for each individual conference will be selected to give a short oral presentation as part of that conference's program. Presentation slots fill up fast so please submit your abstract ASAP.

SPONSORSHIP OPPORTUNITIES

Our conferences are designed with our sponsors and exhibitors in mind: we create intimate and highly interactive environments so that they can maximize their reach and make long-lasting contacts. Our sponsors and exhibitors benefit from a few of the following:

- Sponsors/exhibitors have the option to receive the delegate list a week before and a week after the conference.
- The exhibit space for the meeting is shared with any other concurrent conferences, providing sponsors and exhibitors with access to a larger audience. The exhibit space is also where all networking functions take place, including coffee, snack stations, breakfast, and the evening reception.
- Your corporate logo will be placed on the cover page of the conference brochures, the proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:

Amber Kempf
Senior Account Executive
amber.kempf@gtcbio.com

SPONSORS

PLATINUM

Myriad RBM, Inc. is the world's leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.

MYRIAD  RBM™

GOLD

Quanterix
high definition diagnostics

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.

SomaLogic measure 1,310 proteins simultaneously from 65 µL of sample with high sensitivity, specificity and reproducibility. We enable biomarker discovery, better understanding of pathways, target identification, target validation and understanding of off-target effects. We can scale our technology from a large plex (1,310 proteins), to individual analytes, and to panels.

SomaLogic



S-BIO is a division of Sumitomo Bakelite Co., Ltd. We offer products and services in 2 categories: glycan related products & services, and high performance labware for cell culture applications. S-BIO has an established Glycan Analysis Laboratory for biomarker discovery & biotherapeutic development and product distribution center in Hudson, NH.

Caprion/Immunecarta is specialized in the design and implementation of immune monitoring assays to assess the phenotypic and functional profiles of immune responses in both pre-clinical and clinical settings (under GLP). We are also leader in Proteomic for the discovery and validation of predictive and prognostic biomarkers using mass spectrometry to rapidly measure the differential expression of proteins from small amounts of biological fluids, tissue, cells and organelles.



CAPRION



Viracor-IBT is a CAP/CLIA accredited laboratory providing large molecule biomarker support for phase I-IV trials. Viracor-IBT has 30+ years of experience in molecular testing, immune response monitoring, allergy/hypersensitivity testing. Expertise includes custom assay design, optimization, transfer and validation. Our streamlined processes provide more options and flexibility for your specific needs.

Since its founding in 1941, **Southern Research** has evaluated approximately half of all FDA-approved anticancer drugs currently on the market for patients. Our cancer therapeutics professionals evaluate hundreds of compounds each year to establish the in vitro biochemical effects and in vivo efficacy of potential anticancer drugs. Our in vitro laboratories include: over 200 human tumor cell lines for multiple-system testing, NCI "consolidated" 12 cell-line panel testing capabilities, efficacy testing using a range of in vitro assays including the hollow-fiber assay system, combination studies including radiosensitization, and rapid screening systems for thorough drug testing in reduced time. Our in vivo laboratories conduct studies: in combination radiation therapy/chemotherapy, with over 80 human xenograft models, in an extensive range of murine tumors, and with an extensive efficacy database of clinically useful agents. Please visit the Southern Research booth to learn more about how we can assist you in your cancer research.



Solving the world's
hardest problems.

SPONSORS

SILVER



Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine.

Swedish company **Olink Bioscience** provides innovative solutions for human protein biomarker research. Proseek® Multiplex enables rapid, high-throughput immunoassay analysis, exceptional data quality, and minimal sample consumption. Disease-focused panels allow simultaneous analysis of 92 biomarkers with 1 µl of sample, and are available as kits or via our fee-for service offering.



COORPORATE



Using novel epigenetic technology, **Epiontis** provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.

AGENDA AT-A-GLANCE

Day 1 - Monday, March 21, 2016

7:00	Registration & Continental Breakfast
7:55	Welcome & Opening Remarks
8:00	Plenary Keynotes
10:00	Morning Networking Break
10:30	Plenary Session: Big Data Analytics for Biomarkers Development
12:00	Lunch on Your Own
1:30	Plenary Session: Novel Technologies in Biomarker Development
3:00	Afternoon Networking Break
3:30	Plenary Panel Discussion: Companion Diagnostics Dev. & Partnering Strategies Plenary Panel Discussion: Non-profits & Patient Perspectives on Precision Medicine
6:00	Evening Reception & Poster Session

Day 2 - Tuesday, March 22, 2016

7:30	Continental Breakfast		
	8th Oncology Biomarkers	4th Neurological Biomarkers	4th Inflammatory & Immunological Biomarkers
8:00	Session I: Minimally Invasive & Non-invasive Approaches in Cancer	Session I: Imaging Approaches in CNS Drug Discovery & Development	Session I: Biomarkers of Early Progressive Inflammatory & Immunological Diseases
10:05	Morning Networking Break		
10:50	Session II: Emerging Discovery Pipelines	Session II: CSF & Blood Based Biomarker Approaches	Session II: Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
12:30	Lunch Provided by GTCbio		
1:35	Session III: Immuno-Oncology Biomarker Discovery	Session III: Developments in Neurological & Neurodegenerative Disorders	Session III: Novel Approaches to Immunological Biomarkers
3:10	Afternoon Networking Break		
4:00	Session III (Cont.): Immuno-Oncology Biomarker Discovery	Session IV: Biomarker Development in Neuropsychiatric Disorders	Session IV: Microbiomes in Immune Modulation & Inflammatory Diseases
5:30	Day 2 Concludes		

All times are approximate and subject to changes without notice

AGENDA AT-A-GLANCE

Day 3 - Wednesday, March 23, 2016

7:30	<i>Continental Breakfast</i>
8:00	Plenary Session: Overcoming Challenges of Clinical Validation & Translation
10:05	<i>Morning Networking Break</i>
10:35	Plenary Session: Overcoming Challenges of Clinical Validation & Translation (cont.) Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Dev.
12:35	<i>Light Refreshments & Conference Concludes</i>

All times are approximate and subject to changes without notice

KEYNOTE & FEATURED SPEAKERS



Rigors and Reproducibility in Cancer Biomarker Validation: The NCI's Early Detection Research Network Approach

Sudhir Srivastava
National Cancer Institute, NIH



Creating Personalized Diagnostics Ecosystems

Alan Wright
Roche Diagnostics



Polymorphic Structural Variant Biomarker Strategy for Complex Neurodegenerative Diseases: Alzheimer's Disease, Lewy-Body Variant of Alzheimer's Disease and Amyotrophic Lateral Sclerosis

Allen Roses
**Duke University Medical Center
Zinfandel Pharmaceuticals**



Precision Medicine: The Future of Data Driven Healthcare

Claudio Carini
Pfizer



Tumor-associated Macrophage and Tumor-infiltrating Lymphocyte as Predictive Biomarker in Metastatic Renal Cell Carcinoma

Jean-François Martini
Pfizer



Plenary Session: Overcoming Challenges of Clinical Validation & Translation.

Andrew Schade
Eli Lilly

DISTINGUISHED SPEAKERS



Plenary Session: Big Data Analytics for Biomarkers Development.

Mohammad Afshar
Ariana Pharma



Session: Developments in Neurological & Neurodegenerative Disorders

Kenneth Marek
Institute for Neurodegenerative Disorders



Session: Novel Approaches to Immunological Biomarkers

Andrea Ballagi
Olink Biosciences



Development of a Clinical Cell-Free DNA Assay as an Alternative DNA Source for Cancer Molecular Profiling

John Mayfield
Foundation Medicine




Novel Multiplexed MRM and iMALDI Assays for Protein Biomarker Evaluation

Christoph Borchers
University of Victoria



Plenary Session: Overcoming Challenges of Clinical Validation & Translation

John McKinley
Precision Medicine Catapult



Session: Emerging Discovery Pipelines

Zach Boyd
Genentech



Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies

Patricia McLoughlin
Qiagen

DISTINGUISHED SPEAKERS (cont.)



Session: CSF & Blood Based Biomarker Approaches

Daniel Chelsky
Caprion Proteomics



Deep Phenotyping by Flow Cytometry Combined with Single Cell Gene Expression as a New Strategy for Biomarker Discovery in Affinity-enhanced NY-ESO-1-TCR Adoptive Cell Therapy

Luca Melchiori
Adaptimmune



Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development.

B. Melina Cimler
Adaptive Biotechnologies



Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development.

Alan Mertz
American Clinical Laboratory Association (ACLA)



New Technologies Help Overcome Challenges Selecting Target Specific Antibodies for IHC Applications

John Cogswell
Bristol-Meyers Squibb



The Future of Mass Spectrometry-based Protein Lab Tests

Dobrin Nedelkov
Arizona State University



Any Biomarker – One Priority: Quality

Anka Ehrhardt
Bristol-Myers Squibb



Development of Biomarkers for Use in Cancer Immunotherapy: PD-L1 and Beyond

Sandip Patel
University of California San Diego



Immune Activation by the Toll-like Receptor 8 Agonist Motolimod is not Compromised in Advanced-Stage Cancer Patients

Gregory Dietsch
VentiRX Pharmaceuticals



Session: Developments in Neurological & Neurodegenerative Disorders

Jane Paulsen
The University of Iowa



Plenary Panel Discussion: Non-profits Perspectives on Precision Medicine

Angela Dobes
Crohn's & Colitis Foundation



A Patient-centric Strategy for the Discovery, Development and Delivery of Multiplexed Blood Protein Biomarkers

Stephen Pennington
University College Dublin



Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development

Julie Engel
Ventana Medical Systems, Roche



CTCs as Exploratory Biomarkers in Early Clinical Trials

Steven Pirie-Shepherd
Pfizer

DISTINGUISHED SPEAKERS (cont.)



Session: Plenary Session: Overcoming Challenges of Clinical Validation & Translation.

David Ferry
Eli Lilly



Session: Imaging Approaches in CNS Drug Discovery & Development

Diana Price
Neuropore Therapies



Opportunities and Challenges in Measuring Immune Response in Different Cancer Types and Microenvironment

Fiona Ginty
GE Healthcare



Case Study: Oxidized Macrophage Migration Inhibitory Factor (oxMIF) Is a New Potential Biomarker in Oncology

Nicolas Sabarth
Baxalta



Session: Minimally Invasive & Non-invasive Approaches in Cancer

Charles Glaus
Amgen



Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies

Jack Sawyer
Boston Healthcare



Product Development and Regulatory Submission Strategies for Next-Generation Sequencing in Liquid Biopsies for Oncology Patients

Federico Goodsaid
TOMA Bioscience



Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development

Danielle Scelfo
Hologic



Plenary Session: Big Data Analytics for Biomarkers Development.

Michael Hale
Baxalta



Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies

John Schilling
Eli Lilly



Plenary Panel Discussion: Non-profits & Patient Perspectives on Precision Medicine.

Kathy Hammitt
Sjogren's Syndrome Foundation



Session: Developments in Neurological & Neurodegenerative Disorders

Märta Segerdahl
H. Lundbeck A/S



Session: Minimally Invasive & Non-invasive Approaches in Cancer

Michael Heller
University of California San Diego



Plenary Session: Overcoming Challenges of Clinical Validation & Translation

Anuraag Shrivastav
University of Winnipeg

DISTINGUISHED SPEAKERS (cont.)



Session: Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases

Ulrich Hoffmueller
Epiontis



Session: Biomarkers of Early Progressive Inflammatory & Immunological Diseases

Kathy Sivils
**Oklahoma Medical Research Foundation
University of Oklahoma Health Sciences Center**



Session: CSF & Blood Based Biomarker Approaches

Samantha Hutte
Michael J. Fox Foundation



Mode of Action Biomarker Discovery in Systemic Sclerosis Patients Treated With Tocilizumab

Thierry Sornasse
Genentech



Application of Real World Evidence to Assess Clinical & Economic Utility of Biomarkers

Usman Iqbal
AstraZeneca



Potential Biomarkers in Models of Neuropathic and Visceral Pain: P2X7R Inhibition

Roland Staal
Formerly of Lundbeck Research USA



Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies

Nicole Jean
AstraZeneca



Session: Developments in Neurological & Neurodegenerative Disorders

Margaret Sutherland
National Institute of Neurological Disorders & Stroke, NIH



Extracellular RNAs as Readouts for CNS Injury and Disease

Kendall Jensen
Translational Genomics Research Institute (TGen)



Supporting Biomarkers Research and Development in an Open Ecosystem

Sándor Szalma
Janssen R&D




New Frontiers in Blood-Based Biomarkers

Andreas Jeromin
Quanterix



Plenary Session: Novel Technologies in Biomarker Development.

Paul Tume
University of California Los Angeles



OASIS: A Web-based Platform for Exploring Cancer Multi-omics Data

Zhengyan Kan
Pfizer



CATS - A Novel DNA Library Preparation Method for Ultrasensitive Deep Sequencing of Extracellular Circulating Nucleic Acids

Andrey Turchinovich
German Cancer Research Center/Uni-Clinic Heidelberg

DISTINGUISHED SPEAKERS (cont.)




Session: Emerging Discovery Pipelines

Ann Kapoun
OncoMed Pharmaceuticals



Leveraging Heterogeneous Public Data for Identifying Robust and Reproducible Biomarkers

Purvesh Khatri
Stanford University



Session: CSF & Blood Based Biomarker Approaches

Hartmuth Kolb
Janssen R&D



Characterization of SF3B1-mut Associated Aberrant Splice Variant Transcripts and Their Potential Use as Biomarkers for Novel Splicing Modulators

Pavan Kumar
H3 Biomedicine



Novel Biomarkers of Kidney Injury and Progression of Kidney Disease

Mahmoud Loghman-Adham
Baxter Healthcare



Practical Strategies for NGS Based Biomarker Development

John Lubniewski
HTG Molecular Diagnostics



Plenary Panel Discussion: Non-profits & Patient Perspectives on Precision Medicine

Douglas Macdonald
CHDI Foundation



Applying Big-data and Mathematical Modeling to Biomarker Discovery

Parag Mallick
Stanford University



Use of Reticulocyte Hemoglobin (Ret-He/CHr) as a Biomarker of Erythropoiesis and Anemia Assessment

Denise Uettwiller-Geiger
John T. Mather Memorial Hospital



Circulating Brain-enriched MicroRNAs as Biomarkers for Early Detection and Differential Diagnosis of Neurodegenerative Diseases

Samuil Umansky
DiamiR




Session: Biomarkers of Early Progressive Inflammatory & Immunological Diseases

Kai Wang
Institute for Systems Biology



Session: Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases

Chan Whiting
Aduro Biotech



Session: Biomarkers of Early Progressive Inflammatory & Immunological Diseases

Kenneth W. Witwer
Johns Hopkins University School of Medicine



Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development.

Rina Wolf
XIFIN



Plenary Session: Big Data Analytics for Biomarkers Development.

Diane Wuest
GNS Healthcare



Clinical Biomarker Development: Well Begun is Half Done

Xuemei Zhao
Merck

CONFERENCE DETAILS

REGISTRATION

Early Registration Discount:

20% until January 21, 2016

10% until February 21, 2016

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**To register online, visit: www.gtcbio.com/register/biomarkers-summit

	Commercial	Academic / Govt	Student
Summit	2395.00	1195.00	995.00
Biomarker Summit + Ocular	2595.00	1295.00	1095.00
Individual Conference	1895.00	895.00	745.00

QUICK REGISTRATION - FAX TO (626) 466-4433

First Name: _____ Last Name: _____

Title: _____ Company: _____

Discount Coupon Code: _____

Card #: _____ Exp. Date: _____ CSV #: _____

Cardholder Name: _____

Signature: _____

Billing Address: _____

City: _____ State: _____ Zip: _____

VENUE

Westin San Diego

400 West Broadway

San Diego, CA 92101

1 (619) 239-4500

Discounted Group Rate: \$215.00 per night**Discount Deadline: March 7, 2016**

Toll Free Reservations: 1-888-575-6397

Mention GTCbio to receive the group rate.

Reservations by phone: 1 (888) 627-9033

Online Reservations:

<https://www.starwoodmeeting.com/Book/2016GTCbio>

PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form [here](#). Fill out the order form and fax it to 1 (626) 433-4433 or email it to proceedings@gtcbio.com.